The association between SHISA3 promoter methylation status and the clinicopathological parameters of the LSCC patients, including age, gender, smoking behavior, histological grade, clinical stage, tumor stage, and lymph node metastasis, was assessed (Table 2). This evidence concerns the gene SHISA3 and metastatic malignant neoplasm in the lymph nodes.